http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20010072368-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 |
| filingDate | 1999-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20010072368-A |
| titleOfInvention | Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors |
| abstract | The present invention relates to respiratory diseases, allergic diseases, rheumatic diseases, weight control diseases, inflammatory diseases and central nervous system diseases such as asthma, chronic obstructive pulmonary disease, adult respiratory disease syndrome, poison shock, fibrosis, pulmonary hypersensitivity disease Formulas useful for the treatment of allergic rhinitis, atopic dermatitis, psoriasis, weight control, rheumatoid arthritis, cachexia, Crohn's disease, ulcerative colitis, arthritis and other inflammatory diseases, depression, multi-infarct dementia and AIDS A compound or pharmaceutically acceptable salt of In n n Formula In n n n n n n n Wheren n n R 1 and R 2 are each independently hydrogen, (C 1 -C 6 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 6 -C 10 ) aryl, (C 5 -C 9 ) heteroaryl and ( C 2 -C 9 ) heterocycloalkyl, wherein the alkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl group is optionally halo, hydroxy, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, amino, (C 1 -C 6 ) alkylamino, ((C 1 -C 6 ) alkyl) 2 amino, thio, (C 1 -C 6 ) alkylthio, cyano, carboxy, carboxy ( C 1 -C 6 ) alkyl, hydroxy (C 1 -C 6 ) alkyl, (C 1 -C 6 ) acyl, aminosulfonyl, (C 1 -C 6 ) alkylaminosulfonyl or ((C 1 -C 6 ) alkyl) 2 aminosulfonyl,n n n R 3 is hydrogen, halo, hydroxy, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, amino, (C 1 -C 6 ) alkylamino, ((C 1 -C 6 ) alkyl) 2 amino, thio, (C 1 -C 6 ) alkylthio, carboxy, carboxy (C 1 -C 6 ) alkyl, hydroxy (C 1 -C 6 ) alkyl, (C 1 -C 6 ) acyl, aminosulfonyl , (C 1 -C 6 ) alkylaminosulfonyl or ((C 1 -C 6 alkyl) 2 aminosulfonyl. |
| priorityDate | 1998-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 180.